AINDEX
Markets

Grifols, S.A. (GRFS)

GRFSNASDAQ-GSBiotechnology: Pharmaceutical Preparations

$8.69

+0.2600 (+3.08%) today

Closed, Nov 9, 4:00 PM ET

+3.08% 1D
Market cap
$5.97bn
P/E
–
EPS, last 4 quarters
–
Dividend yield
–
Day range
–
52-week range
$6.96 to $9.77
Average volume
624.7k
Previous close
$8.43

Analysts

1 covering

Hold0 buy, 1 hold, 0 sell

Targets a year out average $9.00, +3.6% from here

$9.00now $8.69$9.00

Earnings

next estimate $0.3300

Next report

Financials

No quarterly figures from the source.

News

8 latest

The company

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries. Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care. A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ-GS
Region
Europe

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.